It has long been known that a hallmark of Alzheimer’s disease, and most other neurodegenerative diseases, is the clumping together of insoluble protein aggregates in the brain.
FDA approves Skyline Therapeutics’ IND for macular degeneration trial – Pharmaceutical Technology
nAMD, which leads to severe visual impairment, is estimated to affect over 200 million people worldwide. Image credit: Shutterstock/air009. Chinese gene therapy company Skyline will
July 4, 2023